The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administrations key healthcare priorities
If insurance excludes weight-loss medications (common), compounded tirzepatide at $349-$549/month is usually the cheapest legitimate route, well below brand cash pay
At the same time, symptoms affecting the skin can sometimes be dermatological reactions , meaning reactions involving the skin itself
Its also not FDA approved, since its considered a supplement, not a medication
Who Should Exercise Particular Caution: Pregnant or Nursing Women: No safety data exists for BPC-157 use during pregnancy or lactation
The data from the ATTAIN-1 trial, published in September 2025, look good